Trials / Withdrawn
WithdrawnNCT05312372
S095033 in Combination With Paclitaxel as 2nd- or 3rd-line Treatment in Participants With Advanced or Metastatic ESCC
A Phase 1/2, Open -Label, Multicenter Trial Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antineoplastic Activity of S095033 (MAT2A Inhibitor) in Combination With Paclitaxel in Participants With Advanced or Metastatic Esophageal Squamous Cell Carcinoma (ESCC)
- Status
- Withdrawn
- Phase
- Phase 1 / Phase 2
- Study type
- Interventional
- Enrollment
- 0 (actual)
- Sponsor
- Institut de Recherches Internationales Servier · Academic / Other
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The purpose of this study is to determinate the safety profile, tolerability, pharmacokinetics, and preliminary antineoplastic activity of S095033 in combination with paclitaxel in participants with advanced or metastatic esophageal squamous cell carcinoma (ESCC)
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Combination (S095033 + paclitaxel) | Phase 1- dose escalation S095033 ; paclitaxel started at 80 mg/m²,(IV) Phase 2 - S095033 at RP2D; paclitaxel started at 80 mg/m²,(IV) |
Timeline
- Start date
- 2025-05-01
- Primary completion
- 2026-06-01
- Completion
- 2026-06-01
- First posted
- 2022-04-05
- Last updated
- 2026-02-17
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT05312372. Inclusion in this directory is not an endorsement.